10x Genomics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expiring at the 2029 annual meeting of stockholders or until each such director's successor is duly elected and qualified or until each such director's earlier death, resignation, disqualification or removal: Benjamin J. Hindson

10x Genomics, Inc.’s own tally for this item (“Elect Director: Benjamin J. Hindson”): 162,942,766 for, 16,761,532 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 49,127,161 for, 3,203,209 against, 10,077 abstained.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Description as filed by funds: Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expiring at the 2029 annual meeting of stockholders or until each such director's successor is duly elected and qualified or until each such director's earlier death, resignation, disqualification or removal: John R. Stuelpnagel

10x Genomics, Inc.’s own tally for this item (“Elect Director: John R. Stuelpnagel”): 155,628,365 for, 24,072,179 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 45,696,450 for, 6,633,920 against, 10,077 abstained.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Description as filed by funds: Election of the Class I directors listed in the accompanying proxy statement, to serve a three-year term expiring at the 2029 annual meeting of stockholders or until each such director's successor is duly elected and qualified or until each such director's earlier death, resignation, disqualification or removal: Serge Saxonov

10x Genomics, Inc.’s own tally for this item (“Elect Director: Serge Saxonov”): 164,137,381 for, 15,559,860 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 49,924,039 for, 2,466,331 against, 10,077 abstained.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Description as filed by funds: A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and

10x Genomics, Inc.’s own tally for this item (“3. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers”): 176,677,540 for, 2,828,730 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in more detail in the Company's definitive proxy state…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 79 managers: 50,506,976 for, 1,815,393 against, 210,078 abstained, 1 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 261 managers: 52,704,913 for, 2,338,896 against, 530,146 abstained, 732 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;

10x Genomics, Inc.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 197,719,939 for, 458,231 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 52,330,369 for, 10,077 abstained.

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.